Published in Int J Ophthalmol on June 18, 2012
Molecular mechanisms of subretinal fibrosis in age-related macular degeneration. Exp Eye Res (2015) 0.86
Aryl hydrocarbon receptor knock-out exacerbates choroidal neovascularization via multiple pathogenic pathways. J Pathol (2014) 0.78
Balancing AhR-Dependent Pro-Oxidant and Nrf2-Responsive Anti-Oxidant Pathways in Age-Related Retinopathy: Is SERPINE1 Expression a Therapeutic Target in Disease Onset and Progression? J Mol Genet Med (2014) 0.77
Interleukin-13 and age-related macular degeneration. Int J Ophthalmol (2017) 0.75
Ranibizumab for neovascular age-related macular degeneration. N Engl J Med (2006) 30.63
Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med (2006) 20.84
Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med (2011) 19.42
TGF-beta signal transduction. Annu Rev Biochem (1998) 17.83
Cellular and molecular mechanisms of fibrosis. J Pathol (2008) 14.01
Role of transforming growth factor beta in human disease. N Engl J Med (2000) 10.17
TGF-beta signaling and the fibrotic response. FASEB J (2004) 9.81
Transforming growth factor beta in tissue fibrosis. N Engl J Med (1994) 9.73
Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol (1990) 3.81
Age-related macular degeneration. N Engl J Med (2000) 3.32
Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology (2011) 2.43
CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature (2009) 2.39
Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest (1989) 2.16
Role for carbohydrate structures in TGF-beta 1 latency. Nature (1989) 2.02
Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Invest Ophthalmol Vis Sci (1994) 1.90
Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol (2009) 1.79
Fibrosis and diseases of the eye. J Clin Invest (2007) 1.79
Physicochemical activation of recombinant latent transforming growth factor-beta's 1, 2, and 3. Growth Factors (1990) 1.72
Immunolocalization of TGF-beta 1, TGF-beta 2, and TGF-beta 3 in the anterior segment of the human eye. Invest Ophthalmol Vis Sci (1993) 1.40
Choroidal neovascularization: a wound healing perspective. Mol Vis (2003) 1.37
Transforming growth factor-beta induces expression of vascular endothelial growth factor in human retinal pigment epithelial cells: involvement of mitogen-activated protein kinases. J Cell Physiol (2003) 1.35
Growth factors in retinal diseases: proliferative vitreoretinopathy, proliferative diabetic retinopathy, and retinal degeneration. Surv Ophthalmol (1992) 1.26
Regulation of VEGF mRNA expression and protein secretion by TGF-beta2 in human retinal pigment epithelial cells. Exp Eye Res (2007) 1.20
Development of subretinal fibrosis after anti-VEGF treatment in neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging (2010) 1.12
Expression of transforming growth factor-beta mRNA in experimental choroidal neovascularization. Curr Eye Res (1997) 1.04
TGF-beta1, TGF-beta receptor II and ED-A fibronectin expression in myofibroblast of vitreoretinopathy. Invest Ophthalmol Vis Sci (2000) 1.02
Establishment of a new animal model of focal subretinal fibrosis that resembles disciform lesion in advanced age-related macular degeneration. Invest Ophthalmol Vis Sci (2011) 0.87
Transforming growth factor-β inhibition decreases diode laser-induced choroidal neovascularization development in rats: P17 and P144 peptides. Invest Ophthalmol Vis Sci (2011) 0.84
Fibroblast proliferation by bleomycin stimulated peripheral blood mononuclear cell factors. J Rheumatol (1999) 0.79
Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial. Am J Ophthalmol (2011) 0.90
Intravitreal bevacizumab for treatment of macular edema secondary to central retinal vein occlusion: eighteen-month results of a prospective trial. J Ocul Pharmacol Ther (2011) 0.86
Intravitreal bevacizumab as primary treatment of choroidal neovascularization secondary to punctate inner choroidopathy: results of a 1-year prospective trial. Retina (2012) 0.82
Increased nitric oxide and vascular endothelial growth factor levels in the aqueous humor of patients with coats' disease. J Ocul Pharmacol Ther (2012) 0.82
Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients. Int J Ophthalmol (2013) 0.81
CTGFsiRNA ameliorates retinal cells apoptosis in streptozotocin-induced diabetic rats. Int J Ophthalmol (2010) 0.78
Interleukin-6 receptor blockade suppresses subretinal fibrosis in a mouse model. Int J Ophthalmol (2014) 0.76
Interleukin-13 and age-related macular degeneration. Int J Ophthalmol (2017) 0.75
Incidence of Charles Bonnet syndrome after intravitreal bevacizumab injection in neovascular age-related macular degeneration. Acta Ophthalmol (2012) 0.75